HK1160148A1 - 人類分揀蛋白的晶體結構及其用於鑒定分揀蛋白的配體的用途 - Google Patents

人類分揀蛋白的晶體結構及其用於鑒定分揀蛋白的配體的用途

Info

Publication number
HK1160148A1
HK1160148A1 HK12100493.8A HK12100493A HK1160148A1 HK 1160148 A1 HK1160148 A1 HK 1160148A1 HK 12100493 A HK12100493 A HK 12100493A HK 1160148 A1 HK1160148 A1 HK 1160148A1
Authority
HK
Hong Kong
Prior art keywords
sortilin
crystal structure
human
identifying ligands
ligands
Prior art date
Application number
HK12100493.8A
Other languages
English (en)
Inventor
Petersen Jens Claus Munck
Poul Nissen
Madsen Peder Sndergaard
Hgh Quistgaard Esben Meldgaard
Grftehauge Morten Keller
Thirup Sren Skou
Cramer Jacob Flyvholm
Andersen Jacob Lauwring
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of HK1160148A1 publication Critical patent/HK1160148A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
HK12100493.8A 2008-04-27 2012-01-16 人類分揀蛋白的晶體結構及其用於鑒定分揀蛋白的配體的用途 HK1160148A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200800592 2008-04-27
PCT/DK2009/050099 WO2009132656A2 (en) 2008-04-27 2009-04-27 Design of specific ligands to sortilin

Publications (1)

Publication Number Publication Date
HK1160148A1 true HK1160148A1 (zh) 2012-08-10

Family

ID=40910794

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12100493.8A HK1160148A1 (zh) 2008-04-27 2012-01-16 人類分揀蛋白的晶體結構及其用於鑒定分揀蛋白的配體的用途

Country Status (8)

Country Link
US (1) US8377701B2 (zh)
EP (1) EP2274327B1 (zh)
JP (1) JP5715045B2 (zh)
KR (1) KR101614558B1 (zh)
CN (1) CN102131826B (zh)
ES (1) ES2730972T3 (zh)
HK (1) HK1160148A1 (zh)
WO (1) WO2009132656A2 (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009155932A2 (en) * 2008-06-25 2009-12-30 H. Lundbeck A/S Modulation of the trpv : vps10p-domain receptor system for the treatment of pain
JP5871249B2 (ja) * 2010-05-31 2016-03-01 国立研究開発法人産業技術総合研究所 成長因子のプロペプチド
JP5952816B2 (ja) * 2010-08-19 2016-07-13 プロビオドルグ エージー グルタミニルシクラーゼの結晶構造
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9783601B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
CA2938019A1 (en) * 2014-01-27 2015-07-30 Medincell Retro-inverso analogs of spadin display increased antidepressant effects
DK3280441T3 (da) 2015-04-07 2021-11-15 Alector Llc Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
AU2016358324B2 (en) * 2015-11-24 2021-03-11 Transfert Plus, S.E.C. Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
CA3010226C (en) * 2015-12-31 2023-02-14 Cyclica Inc. Methods for proteome docking to identify protein-ligand interactions
US11242408B2 (en) * 2016-06-14 2022-02-08 Advanced Biodesign Monoclonal antibody specific for gamma-glutamyl-l-epsilon-lysine for the monitoring of apoptosis
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
JP7438119B2 (ja) * 2017-10-23 2024-02-26 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 細胞外小胞関連疾患のための材料および方法
IL270214B1 (en) 2018-07-13 2024-03-01 Alector Llc Anti-sortilin antibodies and methods of using them
WO2020254683A2 (en) * 2019-06-20 2020-12-24 Aarhus Universitet Sorcs2 crystal structure and uses thereof
EP3881840A1 (en) * 2020-03-19 2021-09-22 Insusense ApS Sortilin antagonists for use inthe treatment of diabetic retinopathy
EP3981394A1 (en) * 2020-10-07 2022-04-13 Insusense ApS A sortilin antagonist for use in the prevention or treatment of hearing loss.
EP4032891A1 (en) * 2021-01-20 2022-07-27 Insusense ApS Pyridine derivatives as modulators of sortilin activity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003002900A (ja) * 2000-08-03 2003-01-08 Inst Of Physical & Chemical Res ウシ・ロドプシンの立体構造
EP1195383A3 (en) 2000-08-03 2002-05-02 Riken Three-dimensional structure of bovine rhodopsin
KR100793263B1 (ko) * 2000-09-19 2008-01-10 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 ＧＳＫ-3β 단백질의 특성확인 및 그것의 이용 방법
JP2003342297A (ja) * 2002-05-30 2003-12-03 National Institute Of Advanced Industrial & Technology ＬｙｓＲタイプ蛋白質ＣｂｎＲの結晶構造
EP1891966B1 (en) * 2002-12-20 2012-02-15 H. Lundbeck A/S Modulation of activity of neurotrophins; screening method
WO2007100718A2 (en) 2006-02-24 2007-09-07 Denise Barbut Neurotensin receptor agonists and opioid receptor agonists
DK2120997T3 (en) * 2006-12-21 2017-05-08 H Lundbeck As MODULATION OF PRO-NEUROTROPHIN ACTIVITY
WO2008086452A2 (en) 2007-01-10 2008-07-17 Columbia University Treatment and prevention of alzheimer's disease

Also Published As

Publication number Publication date
KR20110018324A (ko) 2011-02-23
KR101614558B1 (ko) 2016-04-22
JP2011518791A (ja) 2011-06-30
JP5715045B2 (ja) 2015-05-07
US8377701B2 (en) 2013-02-19
CN102131826A (zh) 2011-07-20
EP2274327B1 (en) 2019-03-27
ES2730972T3 (es) 2019-11-13
WO2009132656A2 (en) 2009-11-05
WO2009132656A3 (en) 2010-01-21
CN102131826B (zh) 2014-07-02
US20110160439A1 (en) 2011-06-30
EP2274327A2 (en) 2011-01-19

Similar Documents

Publication Publication Date Title
HK1160148A1 (zh) 人類分揀蛋白的晶體結構及其用於鑒定分揀蛋白的配體的用途
HK1256622A1 (zh) Il-6的抗體和其用途
EP2309860A4 (en) MONOCYCLIC CYANOENONES AND METHODS OF USE
HK1172896A1 (zh) 化合物和使用方法
HK1161094A1 (zh) 化合物和使用方法
HK1188209A1 (zh) -胺基咪唑並吡啶以及使用方法
PL2373691T3 (pl) PRZECIWCIAŁA ANTY-fXI I SPOSOBY ZASTOSOWANIA
HK1149933A1 (zh) 二氮咔唑和其使用方法
ZA201101651B (en) Anti-notch2 antibodies and methods of use
EP2464227A4 (en) COMPOUNDS AND METHODS OF USE
IL209548A0 (en) Diazacarbazoles and methods of use
IL206125A0 (en) Azaindolizines and methods of use
IL200013A0 (en) Indenoisoquinolinone analogs and methods of use thereof
EP2194065A4 (en) CRYSTALLINE STRUCTURE OF THE EXTRACELLULAR REGION CD147 AND USE THEREOF
IL213973A0 (en) Salt of tetrahydrotriazolopyridine derivative and crystal thereof
IL213695A0 (en) Adhesive compounds and methods of use thereof
HK1138832A1 (en) Heterodimers and methods of using them
EP2268801A4 (en) COMPOSITIONS AND METHODS RELATED TO A HUMAN BOCAVIRUS
EP2291347A4 (en) MANUFACTURE AND USE OF ALKYL P-TOLUATES
GB2459413A8 (en) Perfluoroparacyclophane and methods of synthesis and use thereof
EP2265117A4 (en) INHIBITORS OF PROTEIN PHOSPHATASE-1 AND USES THEREOF
EP2328603A4 (en) APF DERIVATIVES AND USE METHOD
GB0820914D0 (en) Use of CD1d ligands and hydrolases thereof
GB0919317D0 (en) Use of CD1d ligands and hydrolases thereof
PL391561A1 (pl) Nowy kompleks palladu (0) oraz jego zastosowanie w syntezach organicznych

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230429